Company profile
MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology: Pharmaceutical Preparations
Drug pipeline (8)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Baclofen | approved | — | 0 | — |
| BIVALIRUDIN | approved | — | 0 | — |
| Bortezomib | approved | — | 30 | approved |
| Daptomycin | approved | — | 0 | — |
| Levothyroxine Sodium | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06908304 | phase3 | recruiting | 2025-12-08 | 2027-07-31 | Maia Biotechnology | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC |
| NCT05208944 | phase2 | active_not_recruiting | 2022-06-08 | 2027-09-30 | Maia Biotechnology | THIO Sequenced With Cemiplimab in Advanced NSCLC |
FDA applications (10)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 208521 | ANDA | MAIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| ANDA 208749 | ANDA | MAIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| ANDA 210048 | ANDA | MAIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| ANDA 210315 | ANDA | MAIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| ANDA 210777 | ANDA | MAIA PHARMACEUTICALS INC | ||||
Loading… | ||||||